Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study-Reference-Cited by-同舟云学术

Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study

Published:2021-11-02 Issue:6 Volume:22 Page:160-168
ISSN:2578-7489
Container-title:HIV Research & Clinical Practice
language:en
Short-container-title:HIV Research & Clinical Practice

Author:

Pelchen-Matthews Annegret¹^ORCID,Larsen Jakob Friis²,Shepherd Leah¹,Begovac Josip³^ORCID,Pedersen Karen⁴,De Wit Stéphane⁵,Horban Andrzej⁶^ORCID,Jablonowska Elzbieta⁷,Johnson Margaret⁸,Khromova Irina⁹,Losso Marcelo H.¹⁰,Nielsen Lars N.¹¹,Ridolfo Anna Lisa¹²,Schmied Brigitte¹³,Stephan Christoph¹⁴,Yust Israel¹⁵,Curtis Lloyd¹⁶,Vannappagari Vani¹⁷,Ragone Leigh¹⁷,Roen Ashley¹,Raben Dorthe²,Kirk Ole²,Peters Lars²,Mocroft Amanda¹²,

Affiliation:

1. Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK

2. CHIP Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

3. University Hospital of Infectious Diseases, Zagreb, Croatia

4. Hvidovre Universitets Hospital, Hvidovre, Denmark

5. CHU Saint-Pierre, Brussels, Belgium

6. Wojewodzki Szpital Zakazny, Warsaw, Poland

7. Wojewodzki Szpital Specjalistyczny, Olsztyn, Poland

8. Royal Free & University College Medical School, London, UK

9. Centre for HIV/AIDS and Infectious Diseases, Kaliningrad, Russia

10. Hospital J.M. Ramos Mejia, Buenos Aires, Argentina

11. Nordsjaellands Hospital, Hillerod, Denmark

12. Ospedale L. Sacco, Milan, Italy

13. SMZ, Vienna, Austria

14. Medical Dept. 2, Infectious Diseases Unit, Goethe-University Hospital, Frankfurt, Germany

15. Ichilov Hospital, Tel Aviv, Israel

16. GlaxoSmithKline, London, UK

17. ViiV Healthcare, Research Triangle, NC, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/25787489.2021.2003132

Reference26 articles.

1. Recent Advances in the Development of Integrase Inhibitors for HIV Treatment

2. Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?

3. World Health Organization Geneva Switzerland. Update of Recommendations on First- and Second-Line Antiretroviral Regimens. https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1. Updated July 2019. Accessed July 2020.

4. EACS (European AIDS Clinical Society). EACS Guidelines Version 10.0. https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Updated November 2019. Accessed January 2021.

5. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A nanoemulsified formulation of dolutegravir and epigallocatechin gallate inhibits HIV‐1 replication in cellular models;FEBS Letters;2024-05-24

2. Regional variation in NAFLD prevalence and risk factors among people living with HIV in Europe: a meta-analysis;Frontiers in Public Health;2024-01-04

3. Convenience, efficacy, safety, and durability of INSTI-based antiretroviral therapies: evidence from the Italian MaSTER cohort;European Journal of Medical Research;2023-08-18

4. Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review;Expert Review of Anti-infective Therapy;2023-04-20

5. HIV and liver disease;Aids Reviews;2022-06-28